¼¼°èÀÇ Æù´ÙÆÄ¸®´ª½º(Fondaparinux) ½ÃÀå º¸°í¼­(2025³â)
Fondaparinux Global Market Report 2025
»óǰÄÚµå : 1750999
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,235,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,013,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,790,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Æù´ÙÆÄ¸®´ª½º ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀÌ Àü¸ÁµÉ ¿¹Á¤ÀÔ´Ï´Ù. ÀÌ ±â°£¿¡ ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀº ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ ¹ßÀü, ÇÁ¸® ÇÊµå ½Ã¸°Áö ±â¼úÀÇ °³¹ß, AI ´ëÀÀ ÆÄ¸¶ ÄÚºñÁö ¶õ½º ½Ã½ºÅÛÀÇ ÅëÇÕ, »ýÇÕ¼º Á¦Á¶ °øÁ¤, ¿þ¾î·¯ºí ¾à¹°Àü´Þ µð¹ÙÀ̽ºÀÇ ´ëµÎ µîÀÌ ÀÖ½À´Ï´Ù.

Ç÷Àü »öÀüÁõÀÇ ÀÌȯÀ²ÀÌ Áõ°¡ÇÏ´Â °ÍÀº Æù´ÙÆÄ¸®´ª½º ½ÃÀå ¼ºÀåÀ» Å©°Ô ÃËÁøÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ³ëÀÎÀº Ç÷¾× ¼øÈ¯ÀÇ ÀúÇÏ ¹× ±âŸ °Ç°­ °ü·Ã ¹®Á¦¿¡ ÀÇÇØ ½ÉºÎÁ¤¸Æ Ç÷ÀüÁõÀ̳ª Æó »öÀüÁõ µîÀÇ Áúȯ¿¡ °É¸®±â ½¬¿öÁö±â ¶§¹®¿¡ ÀÌ·¯ÇÑ À¯º´·ü Áõ°¡´Â °í·ÉÈ­ Àα¸¿¡ Å©°Ô ±âÀÎÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2025³â 1¿ù ¹Ì±¹ Áúº´ ¿¹¹æ °ü¸® ¼¾ÅÍ(CDC)´Â Á¤¸Æ Ç÷Àü »öÀüÁõ(VTE)¿¡ ÀÇÇØ ¹Ì±¹¿¡¼­ ¿¬°£ 6¸¸-10¸¸¸íÀÌ »ç¸ÁÇØ ¸¹Àº »ç¶÷ÀÌ Àå±â°£¿¡ °ÉÄ£ ÇÕº´Áõ¿¡ ½Ã´Þ¸®°í ÀÖ´Ù°í º¸°íÇß½À´Ï´Ù.

ÇコÄɾî ÁöÃâ Áõ°¡°¡ Æù´ÙÆÄ¸®´ª½º ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ °Ç°­ °ü¸® ÁöÃâ Áõ°¡´Â °í±Þ Ä¡·á ¹× ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¸¸¼º ÁúȯÀÇ ¸¸¿¬ ¹× ´õ ¸¹Àº °Ç°­ °ü¸® ¼­ºñ½º¸¦ ÇÊ¿ä·Î ÇÏ´Â ³ëÈ­·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. Æù´ÙÆÄ¸®´ª½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó, ƯÈ÷ ½ÉÇ÷°ü ÁúȯÀ̳ª Ç÷Àü »öÀüÁõÀÇ Ä¡·á¿¡ °É¸®´Â ÀÇ·áºñµµ Áõ°¡ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 5¿ù ¿µ±¹ Åë°èûÀº 2022³âºÎÅÍ 2023³â±îÁö ÀÇ·áºñ ÁöÃâÀÌ 5.6% Áõ°¡ÇÏ¿© 2022³âÀÇ 0.9% ¼ºÀå·ü¿¡ ºñÇØ ±Þ°ÝÈ÷ Áõ°¡Çß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, Äڷγª ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Fondaparinux is a synthetic anticoagulant that works by selectively inhibiting Factor Xa, preventing the formation of blood clots. It is commonly used to reduce the risk of thromboembolic events in patients at risk.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main uses of fondaparinux include treating deep vein thrombosis (DVT) and pulmonary embolism. Deep vein thrombosis (DVT) is a condition in which a blood clot forms in a deep vein, usually in the legs, and can lead to serious complications if left untreated. Fondaparinux is typically administered through various routes, including parenteral methods such as injections and pre-filled syringes. It is available in different dosage forms, primarily injections. The drug is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. Key end users include hospitals, specialty clinics, and other healthcare providers.

The fondaparinux market research report is one of a series of new reports from The Business Research Company that provides fondaparinux market statistics, including the fondaparinux industry global market size, regional shares, competitors with the fondaparinux market share, detailed fondaparinux market segments, market trends, and opportunities, and any further data you may need to thrive in the fondaparinux industry. This fondaparinux market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fondaparinux market size has grown strongly in recent years. It will grow from$1.85 billion in 2024 to $2.00 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth during the historic period can be attributed to the rising incidence of venous thromboembolism, an increase in surgical procedures, an aging population, global healthcare improvements, and the growing preference for injectable anticoagulants.

The fondaparinux market size is expected to see strong growth in the next few years. It will grow to$2.68 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth during the forecast period can be attributed to the growing prevalence of obesity, rising awareness of thrombosis prophylaxis, government support and reimbursement policies, and the increase in high-risk surgical procedures. Key trends expected in this period include advancements in drug delivery systems, the development of pre-filled syringe technology, the integration of AI-enabled pharmacovigilance systems, biosynthetic manufacturing processes, and the rise of wearable drug delivery devices.

The rising incidence of thromboembolic conditions is expected to significantly drive the growth of the fondaparinux market. Thromboembolic conditions occur when blood clots form in blood vessels and obstruct blood flow to vital parts of the body. This increase in prevalence is largely attributed to the aging population, as older individuals are more susceptible to conditions such as deep vein thrombosis and pulmonary embolism due to slower blood circulation and other health-related issues. Fondaparinux is used to prevent and treat these conditions by inhibiting the formation of harmful blood clots. For example, in January 2025, the Centers for Disease Control and Prevention (CDC) reported that 60,000 to 100,000 fatalities occur annually in the United States due to venous thromboembolism (VTE), with many individuals suffering from long-term complications. Thus, the rising prevalence of thromboembolic conditions will continue to drive the growth of the fondaparinux market.

Rising healthcare expenditures are expected to fuel the growth of the fondaparinux market. Healthcare expenditures refer to the total financial outlay for medical services, treatments, and healthcare-related products by individuals, governments, and organizations. These rising expenditures are driven by an increased demand for advanced medical treatments and technologies, as well as the growing prevalence of chronic diseases and an aging population requiring more healthcare services. As demand for fondaparinux increases, especially for treating cardiovascular and thromboembolic conditions, healthcare costs also rise. For instance, in May 2024, the Office for National Statistics in the UK reported a 5.6% increase in healthcare expenditure from 2022 to 2023, a sharp rise compared to the 0.9% growth seen in 2022. Therefore, increasing healthcare expenditures will propel the growth of the fondaparinux market.

Key players in the fondaparinux market are focusing on innovations such as pediatric-specific drug development to expand the therapeutic applications of fondaparinux, address unmet medical needs, and enhance treatment options for younger patients with conditions such as venous thromboembolism (VTE). Pediatric drug development involves creating and adjusting medications to ensure they are safe and effective for children, considering their unique physiological and developmental requirements. For example, in December 2024, Mylan N.V., a US-based pharmaceutical company, received approval from the Food and Drug Administration (FDA) for Arixtra in treating VTE in pediatric patients aged 1 year and older, weighing at least 10 kg. Arixtra is also approved for adult conditions, including the prevention of deep vein thrombosis (DVT) and the treatment of acute DVT and pulmonary embolism. The pediatric approval was supported by a retrospective, open-label clinical study involving 366 patients, which showed that 44.9% of participants experienced complete resolution of at least one clot, while 44% had full resolution of all clots.

Major players in the fondaparinux market are Sanofi S.A., Abbott Laboratories Inc., GlaxoSmithKline plc, Viatris Inc., Mylan N.V., Sandoz Group AG, Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Cipla Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Aspen Pharmacare Holdings Limited, Lupin Pharmaceuticals Inc., Zydus Lifesciences Limited, Sihuan Pharmaceutical Holdings Group Ltd., Hefei TNJ Chemical Industry Co. Ltd., Apino Pharma Co. Ltd., Home Sunshine Pharma Co. Ltd., Alchemia Limited, Zhejiang Borui Pharmaceutical Co. Ltd.

North America was the largest region in the fondaparinux market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in fondaparinux report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fondaparinux market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fondaparinux market consists of sales of active pharmaceutical ingredient, injection, and fondaparinux kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fondaparinux Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fondaparinux market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for fondaparinux ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fondaparinux market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Fondaparinux Market Characteristics

3. Fondaparinux Market Trends And Strategies

4. Fondaparinux Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Fondaparinux Growth Analysis And Strategic Analysis Framework

6. Fondaparinux Market Segmentation

7. Fondaparinux Market Regional And Country Analysis

8. Asia-Pacific Fondaparinux Market

9. China Fondaparinux Market

10. India Fondaparinux Market

11. Japan Fondaparinux Market

12. Australia Fondaparinux Market

13. Indonesia Fondaparinux Market

14. South Korea Fondaparinux Market

15. Western Europe Fondaparinux Market

16. UK Fondaparinux Market

17. Germany Fondaparinux Market

18. France Fondaparinux Market

19. Italy Fondaparinux Market

20. Spain Fondaparinux Market

21. Eastern Europe Fondaparinux Market

22. Russia Fondaparinux Market

23. North America Fondaparinux Market

24. USA Fondaparinux Market

25. Canada Fondaparinux Market

26. South America Fondaparinux Market

27. Brazil Fondaparinux Market

28. Middle East Fondaparinux Market

29. Africa Fondaparinux Market

30. Fondaparinux Market Competitive Landscape And Company Profiles

31. Fondaparinux Market Other Major And Innovative Companies

32. Global Fondaparinux Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Fondaparinux Market

34. Recent Developments In The Fondaparinux Market

35. Fondaparinux Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â